

Derya Tilki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/972956/publications.pdf>

Version: 2024-02-01

183
papers

5,920
citations

101543

36
h-index

95266

68
g-index

184
all docs

184
docs citations

184
times ranked

5140
citing authors

#	ARTICLE	IF	CITATIONS
1	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancerâ€™2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	1.9	1,545
2	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part IIâ€™2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	1.9	633
3	Urine Markers for Detection and Surveillance of Nonâ€™Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2011, 60, 484-492.	1.9	176
4	Biomarkers in prostate cancer â€™ Current clinical utility and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 180-193.	4.4	135
5	Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy. <i>European Urology</i> , 2016, 69, 584-589.	1.9	119
6	18F-Fluoroethylcholine PET/CT Identifies Lymph Node Metastasis in Patients with Prostate-Specific Antigen Failure After Radical Prostatectomy but Underestimates Its Extent. <i>European Urology</i> , 2013, 63, 792-796.	1.9	78
7	Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. <i>European Urology</i> , 2019, 76, 106-114.	1.9	77
8	A comparative study of robotâ€™assisted and open radical prostatectomy in 10Âˆ790 men treated by highly trained surgeons for both procedures. <i>BJU International</i> , 2019, 123, 1031-1040.	2.5	76
9	External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. <i>European Urology</i> , 2019, 75, 896-900.	1.9	74
10	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020, 78, 661-669.	1.9	74
11	Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer after Radical Prostatectomy. <i>Journal of Urology</i> , 2015, 193, 484-490.	0.4	66
12	The effect of age on functional outcomes after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 203.e11-203.e18.	1.6	66
13	Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality. <i>JAMA Oncology</i> , 2019, 5, 213.	7.1	62
14	Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches. <i>Journal of Urology</i> , 2019, 202, 725-731.	0.4	62
15	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. <i>European Urology</i> , 2018, 74, 376-386.	1.9	58
16	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. <i>European Urology</i> , 2017, 71, 330-336.	1.9	57
17	Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: Results from a single institution series. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 508-514.	1.6	55
18	Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. <i>European Urology Focus</i> , 2016, 2, 499-505.	3.1	55

#	ARTICLE	IF	CITATIONS
19	Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. <i>Journal of Clinical Oncology</i> , 2021, 39, 2284-2293.	1.6	54
20	Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. <i>Journal of Urology</i> , 2020, 203, 338-343.	0.4	53
21	Postoperative complications of contemporary open and robotâ€ assisted laparoscopic radical prostatectomy using standardised reporting systems. <i>BJU International</i> , 2018, 122, 801-807.	2.5	52
22	Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery. <i>European Urology Focus</i> , 2019, 5, 50-53.	3.1	52
23	Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome. <i>European Urology</i> , 2010, 58, 112-117.	1.9	51
24	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	1.9	51
25	External Validation of the CAPRA-S Score to Predict Biochemical Recurrence, Metastasis and Mortality after Radical Prostatectomy in a European Cohort. <i>Journal of Urology</i> , 2015, 193, 1970-1975.	0.4	50
26	Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. <i>European Urology Focus</i> , 2019, 5, 171-178.	3.1	50
27	Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy. <i>Journal of Urology</i> , 2015, 193, 479-483.	0.4	46
28	Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. <i>European Urology Oncology</i> , 2020, 3, 565-581.	5.4	46
29	Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. <i>European Urology Focus</i> , 2017, 3, 615-620.	3.1	44
30	High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. <i>European Urology</i> , 2017, 71, 848-850.	1.9	44
31	Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria. <i>BJU International</i> , 2016, 117, 55-61.	2.5	43
32	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>Prostate</i> , 2018, 78, 469-475.	2.3	40
33	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. <i>European Urology</i> , 2018, 73, 674-683.	1.9	40
34	Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with <sc>pN</sc> 1 prostate cancer treated with radical prostatectomy. <i>BJU International</i> , 2017, 119, 717-723.	2.5	39
35	Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organâ€ confined prostate cancer. <i>Prostate</i> , 2019, 79, 1832-1836.	2.3	38
36	Heterogeneity in Dx ³ Amico classificationâ€ based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 329.e13-329.e19.	1.6	37

#	ARTICLE	IF	CITATIONS
37	Local treatment for metastatic prostate cancer: A systematic review. <i>International Journal of Urology</i> , 2018, 25, 390-403.	1.0	37
38	Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a German Tertiary-care Center. <i>European Urology Focus</i> , 2021, 7, 95-101.	3.1	37
39	Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline. <i>Journal of Urology</i> , 2017, 198, 354-361.	0.4	36
40	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. <i>European Urology</i> , 2022, 81, 337-346.	1.9	33
41	Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H. <i>World Journal of Urology</i> , 2020, 38, 1459-1464.	2.2	32
42	Tumor Characteristics and Oncologic Outcome after Radical Prostatectomy in Men 75 Years Old or Older. <i>Journal of Urology</i> , 2016, 196, 89-94.	0.4	31
43	Association between Lymph Node Counts and Oncological Outcomes in Lymph Node Positive Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 248-255.	3.1	30
44	pT3 Substaging is a Prognostic Indicator for Lymph Node Negative Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2010, 184, 470-474.	0.4	29
45	Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 399-408.	3.1	29
46	Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 139-148.	3.9	28
47	Survival benefit of local versus no local treatment for metastatic prostate cancer—Impact of baseline PSA and metastatic substages. <i>Prostate</i> , 2018, 78, 753-757.	2.3	27
48	How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. <i>BJU International</i> , 2018, 122, 823-830.	2.5	27
49	Salvage therapy for prostate cancer after radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 643-668.	3.8	26
50	The effect of BMI on clinicopathologic and functional outcomes after open radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 297-302.	1.6	25
51	The Impact of Anxiety and Depression on Surgical and Functional Outcomes in Patients Who Underwent Radical Prostatectomy. <i>European Urology Focus</i> , 2020, 6, 1199-1204.	3.1	25
52	Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 296.e21-296.e29.	1.6	24
53	Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. <i>Prostate</i> , 2018, 78, 676-681.	2.3	23
54	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. <i>World Journal of Urology</i> , 2018, 36, 7-13.	2.2	23

#	ARTICLE	IF	CITATIONS
55	Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e130-e139.	1.9	23
56	Accuracy of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography for the Detection of Lymph Node Metastases Before Salvage Lymphadenectomy. <i>European Urology Focus</i> , 2020, 6, 71-73.	3.1	23
57	Ultrasensitive Prostate Specific Antigen and its Role after Radical Prostatectomy: A Systematic Review. <i>Journal of Urology</i> , 2015, 193, 1525-1531.	0.4	22
58	Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. <i>European Urology Focus</i> , 2019, 5, 807-814.	3.1	22
59	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. <i>International Journal of Urology</i> , 2021, 28, 862-869.	1.0	22
60	Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. <i>World Journal of Urology</i> , 2017, 35, 199-206.	2.2	19
61	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. <i>Cancer Epidemiology</i> , 2018, 56, 118-125.	1.9	19
62	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. <i>European Urology Oncology</i> , 2018, 1, 314-320.	5.4	19
63	Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2018, 74, 693-696.	1.9	19
64	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 742-751.	3.1	19
65	EORTC Progression Score Identifies Patients at High Risk of Cancer-Specific Mortality After Radical Cystectomy for Secondary Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 278-286.	1.9	18
66	Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. <i>World Journal of Urology</i> , 2018, 36, 1067-1072.	2.2	18
67	Impact of prostate volume on oncologic, perioperative, and functional outcomes after radical prostatectomy. <i>Prostate</i> , 2015, 75, 1436-1446.	2.3	17
68	Low Other Cause Mortality Rates Reflect Good Patient Selection in Patients with Prostate Cancer Treated with Radical Prostatectomy. <i>Journal of Urology</i> , 2016, 196, 82-88.	0.4	17
69	Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment. <i>World Journal of Urology</i> , 2017, 35, 1833-1839.	2.2	17
70	Timing of radiotherapy after radical prostatectomy. <i>Lancet</i> , The, 2020, 396, 1374-1375.	18.7	17
71	Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 830.e17-830.e26.	1.6	17
72	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. <i>World Journal of Urology</i> , 2012, 30, 807-814.	2.2	16

#	ARTICLE	IF	CITATIONS
73	Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 1399-1407.	2.2	16
74	Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 527.e21-527.e28.	1.6	16
75	68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy. <i>European Urology Focus</i> , 2021, 7, 288-293.	3.1	16
76	Small renal masses in the elderly: Contemporary treatment approaches and comparative oncological outcomes of nonsurgical and surgical strategies. <i>Investigative and Clinical Urology</i> , 2016, 57, 231.	2.0	15
77	Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 160-168.	5.4	15
78	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 105-113.e2.	1.9	15
79	Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?. <i>Cancer Epidemiology</i> , 2019, 58, 83-88.	1.9	15
80	Incidence rates and contemporary trends in primary urethral cancer. <i>Cancer Causes and Control</i> , 2021, 32, 627-634.	1.8	15
81	Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. <i>Prostate</i> , 2021, 81, 874-881.	2.3	15
82	Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 119.e11-119.e18.	1.6	14
83	Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer. <i>World Journal of Urology</i> , 2017, 35, 1031-1036.	2.2	14
84	The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 623-631.	1.0	14
85	Comparison of intra- and postoperative analgesia and pain perception in robot-assisted vs. open radical prostatectomy. <i>World Journal of Urology</i> , 2020, 38, 1451-1457.	2.2	14
86	Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort. <i>Prostate</i> , 2021, 81, 849-856.	2.3	14
87	Anatomical Fundamentals and Current Surgical Knowledge of Prostate Anatomy Related to Functional and Oncological Outcomes for Robotic-Assisted Radical Prostatectomy. <i>Frontiers in Surgery</i> , 2021, 8, 825183.	1.4	14
88	Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death. <i>Journal of Clinical Oncology</i> , 2022, 40, 2186-2192.	1.6	14
89	Identifying the Most Informative Prediction Tool for Cancer-specific Mortality After Radical Prostatectomy: Comparative Analysis of Three Commonly Used Preoperative Prediction Models. <i>European Urology</i> , 2016, 69, 1038-1043.	1.9	13
90	Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States. <i>World Journal of Urology</i> , 2019, 37, 1305-1313.	2.2	13

#	ARTICLE	IF	CITATIONS
91	Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 184-190.	1.6	13
92	Correlation of MRI-Lesion Targeted Biopsy vs. Systematic Biopsy Gleason Score with Final Pathological Gleason Score after Radical Prostatectomy. <i>Diagnostics</i> , 2021, 11, 882.	2.6	13
93	Effect of prostatic apex shape (Lee types) and urethral sphincter length in preoperative MRI on very early continence rates after radical prostatectomy. <i>International Urology and Nephrology</i> , 2021, 53, 1297-1303.	1.4	12
94	Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. <i>European Urology Focus</i> , 2022, 8, 710-717.	3.1	12
95	Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 69-79.	0.4	12
96	Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210819.	3.2	12
97	Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 243-249.	1.6	11
98	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. <i>European Urology Focus</i> , 2019, 5, 449-456.	3.1	11
99	Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair. <i>Cancers</i> , 2020, 12, 2467.	3.7	11
100	Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. <i>Prostate</i> , 2021, 81, 728-735.	2.3	11
101	The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 962-968.	0.4	11
102	Oncological, functional and perioperative outcomes in transplant patients after radical prostatectomy. <i>World Journal of Urology</i> , 2016, 34, 1101-1105.	2.2	10
103	North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. <i>British Journal of Cancer</i> , 2018, 119, 1552-1556.	6.4	10
104	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2022, 8, 690-700.	3.1	10
105	Immunohistochemistry for Prostate Biopsy: Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making. <i>Current Oncology</i> , 2021, 28, 2123-2133.	2.2	10
106	Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy. <i>Current Oncology</i> , 2021, 28, 4738-4747.	2.2	10
107	A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 395-401.	1.9	9
108	Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e939-e945.	1.9	9

#	ARTICLE	IF	CITATIONS
109	The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 255-258.	3.1	9
110	Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. <i>World Journal of Urology</i> , 2021, 39, 3781-3787.	2.2	9
111	Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1153-e1162.	1.9	8
112	The impact of very high initial PSA on oncological outcomes after radical prostatectomy for clinically localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 379-385.	1.6	8
113	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , 2022, 8, 191-199.	3.1	8
114	Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. <i>Prostate</i> , 2021, 81, 1374-1381.	2.3	8
115	Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1344-1352.	4.9	8
116	The Role of Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients With Gleason 6 Intermediate-risk Prostate Cancer. <i>Urology</i> , 2016, 93, 141-146.	1.0	7
117	Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy. <i>BJU International</i> , 2017, 120, 666-672.	2.5	7
118	Impact of the estimated blood loss during radical prostatectomy on functional outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 298.e11-298.e17.	1.6	7
119	Poor Adherence to International Cancer Prevention Recommendations Among Patients With Prostate Cancer: First Results From the MARTINI-Lifestyle Cohort. <i>European Urology Focus</i> , 2020, 6, 935-940.	3.1	7
120	Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 193-201.	3.9	7
121	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1172-1178.	1.0	7
122	External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 17-24.	1.0	7
123	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 778858.	2.8	7
124	Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. <i>Cancers</i> , 2022, 14, 1222.	3.7	7
125	Outcomes of robotic-assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients. <i>Journal of Surgical Oncology</i> , 2022, 126, 830-837.	1.7	7
126	Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment. <i>World Journal of Urology</i> , 2019, 37, 2657-2662.	2.2	6

#	ARTICLE	IF	CITATIONS
127	Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1253-1259.	1.0	6
128	External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 253-260.	3.9	6
129	Prostate-specific antigen levels of ≤ 4 and > 4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer. <i>Cancer</i> , 2021, 127, 2222-2228.	4.1	6
130	Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy: results from a prospective randomized trial. <i>World Journal of Urology</i> , 2018, 36, 871-876.	2.2	5
131	Prostate cancer rates in patients with initially negative elastography-targeted biopsy vs. systematic biopsy. <i>World Journal of Urology</i> , 2018, 36, 623-628.	2.2	5
132	Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study. <i>International Journal of Urology</i> , 2021, 28, 834-839.	1.0	5
133	Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 59.e7-59.e12.	1.6	5
134	The effect of primary urological cancers on survival in men with secondary prostate cancer. <i>Prostate</i> , 2021, 81, 1149-1158.	2.3	5
135	Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort. <i>European Urology Focus</i> , 2021, 7, 973-979.	3.1	5
136	Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis. <i>Cancers</i> , 2022, 14, 740.	3.7	5
137	MRI as a screening tool for prostate cancer: current evidence and future challenges. <i>World Journal of Urology</i> , 2023, 41, 921-928.	2.2	5
138	Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e380-e389.	1.9	5
139	Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 575.e1-575.e7.	1.6	4
140	Antimicrobial Lubricant Did Not Reduce Infection Rate in Transrectal Biopsy Patients in a Large Randomized Trial Due to Low Complication Rates. <i>European Urology Focus</i> , 2019, 5, 992-997.	3.1	4
141	External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. <i>International Urology and Nephrology</i> , 2020, 52, 59-66.	1.4	4
142	Radical Prostatectomy: Sequelae in the Course of Time. <i>Frontiers in Surgery</i> , 2021, 8, 684088.	1.4	4
143	Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProStone, NCT04271579). <i>BJU International</i> , 2021, 128, 301-303.	2.5	4
144	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. <i>Cancer Causes and Control</i> , 2022, 33, 25-35.	1.8	4

#	ARTICLE	IF	CITATIONS
145	Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort. <i>European Urology</i> , 2021, 80, 400-404.	1.9	4
146	Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. <i>Prostate</i> , 2022, 82, 676-686.	2.3	4
147	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	1.9	4
148	Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates. <i>Prostate</i> , 2022, , .	2.3	4
149	The Decipher Genomic Classifier Independently Improves Prognostication for Patients After Prostatectomy. <i>European Urology</i> , 2018, 73, 176-177.	1.9	3
150	Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 1.e11-1.e16.	1.6	3
151	Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 234.e1-234.e7.	1.6	3
152	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. <i>Cancer Gene Therapy</i> , 2022, 29, 49-61.	4.6	3
153	Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. <i>Prostate</i> , 2022, 82, 78-85.	2.3	3
154	Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 96-96.	1.0	3
155	Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer. <i>Prostate</i> , 2022, 82, 254-259.	2.3	3
156	Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. <i>Prostate</i> , 2022, 82, 687-694.	2.3	3
157	Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer. <i>Prostate</i> , 2022, 82, 949-956.	2.3	3
158	Urethral Sphincter Length but Not Prostatic Apex Shape in Preoperative MRI Is Associated with Mid-Term Continence Rates after Radical Prostatectomy. <i>Diagnostics</i> , 2022, 12, 701.	2.6	3
159	Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 161.e9-161.e14.	1.6	3
160	Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence rates. <i>World Journal of Urology</i> , 2016, 34, 1547-1553.	2.2	2
161	Hormonal Treatment for Nonmetastatic Disease Recurrence After Curative Treatment of Prostate Cancer: Only for a Select Few. <i>European Urology</i> , 2016, 69, 821-822.	1.9	2
162	Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>The Prostate</i> . 2018;17. <i>Prostate</i> , 2018, 78, 692-692.	2.3	2

#	ARTICLE	IF	CITATIONS
163	Presence of biopsy Gleason pattern 5+3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns+. Prostate, 2021, 81, 778-784.	2.3	2
164	Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. Prostate, 2021, 81, 1055-1063.	2.3	2
165	Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy. Frontiers in Oncology, 2021, 11, 656444.	2.8	2
166	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer—Current State and Future Perspectives. Cancers, 2022, 14, 147.	3.7	2
167	Full functional-length urethral sphincter- and neurovascular bundle preservation improves long-term continence rates after robotic-assisted radical prostatectomy. Journal of Robotic Surgery, 2022, , 1.	1.8	2
168	Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy. Surgical Oncology, 2022, 42, 101783.	1.6	2
169	Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level. Prostate, 2022, 82, 1210-1218.	2.3	2
170	Is 68 Ga-Prostate-specific Membrane Antigen—ligand Positron Emission Tomography/Computed Tomography Ready To Simplify the Conundrum of Biochemically Recurrent Prostate Cancer?. European Urology, 2018, 73, 662-663.	1.9	1
171	Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer. BJU International, 2018, 122, 721-722.	2.5	1
172	Getting the Balance Right—The Benefits and Uncertainties of Focal Therapy for Significant Prostate Cancer. European Urology, 2018, 74, 430-431.	1.9	1
173	Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer. European Urology Oncology, 2021, 4, 817-820.	5.4	1
174	Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages—Does extent of tumor involvement matter?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e1-637.e7.	1.6	1
175	Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. Cancer Causes and Control, 2022, 33, 769-777.	1.8	1
176	Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	1
177	Re: Clinical Outcomes for Patients with Gleason Score 9–10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. European Urology, 2016, 70, 1079-1080.	1.9	0
178	Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848–50. European Urology, 2017, 72, e176.	1.9	0
179	Reply to Paolo Capogrosso, Francesco Montorsi, and Andrea Salonia's Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848–50. Late Recovery of Erectile Function After Radical Prostatectomy: Should We Modify the Way of Assessment?. European Urology, 2017, 72, e179.	1.9	0
180	Localized Prostate Cancer: Exploring the Boundaries of Current Treatment Paradigms. European Urology Focus, 2020, 6, 199-200.	3.1	0

#	ARTICLE	IF	CITATIONS
181	Reply to Benefitâ€harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10. Cancer, 2021, 127, 4312-4312.	4.1	0
182	Increased risk of postoperative inâ€hospital complications after radical prostatectomy in patients with prior organ transplant. Prostate, 2021, 81, 1294-1302.	2.3	0
183	The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. Frontiers in Oncology, 2021, 11, 754996.	2.8	0